Plant · Scientific monograph
Uncaria tomentosa
Cat's Claw / Uña de Gato
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Immunomodulation Research, Anti-inflammatory Research, Antioxidant Research, Rheumatology Research
Research overview
Historical use
Uncaria tomentosa has been used medicinally for at least 2,000 years by indigenous Amazonian peoples of Peru and other parts of South America, particularly the Asháninka and related communities of the Peruvian rainforest, who prepared decoctions of the root bark and inner bark (cortex) to address inflammation, arthritis, gastric disorders, and infections. The plant derives its common name 'cat's claw' from the curved, claw-like thorns on its woody vine stems. Traditional use was primarily directed at joint pain, wound healing, and conditions associated with general immune weakness [4, 7].
Modern research context
Contemporary research on Uncaria tomentosa has focused primarily on two biological activities supported by laboratory and early clinical evidence: immunomodulation mediated by pentacyclic oxindole alkaloids (POAs), and anti-inflammatory activity involving inhibition of the NF-κB transcription factor and downstream suppression of TNF-α, as demonstrated in cell culture and animal models [2, 3]. A randomised, double-blind, placebo-controlled trial (n=40) in rheumatoid arthritis patients receiving background sulfasalazine or hydroxychloroquine therapy demonstrated a statistically significant reduction in tender joint count (53.2% vs 24.1%, p=0.044) at 24 weeks; the authors characterised this as a modest result from a small preliminary study [1]. Antimutagenic activity has been described in in vitro bacterial assay systems [5]. Importantly, two natural chemotypes of U. tomentosa exist — the pentacyclic oxindole alkaloid (POA) chemotype, associated with immune modulation, and the tetracyclic oxindole alkaloid (TOA) chemotype, which acts on the central nervous system; based on preclinical evidence reviewed by Reinhard (1999), preparations containing both chemotypes are considered therapeutically inferior for immune applications, and POA-standardised extracts are conventionally preferred — though controlled human trials comparing chemotype formulations are lacking [4]. All available evidence for specific clinical indications is preliminary; large-scale independent RCTs are absent [7].
Adverse effects
Uncaria tomentosa was generally well tolerated in the 24-week RCT at doses used for rheumatoid arthritis, with only minor adverse effects reported [1]. Toxicological review indicates low acute toxicity in animal models; however, formal long-term clinical safety data are limited and standardisation of preparations is emphasised as essential to meaningful safety assessment [6]. A single case of allergic interstitial nephritis attributed to cat's claw has been described in the herb nephrotoxicity literature; the original case report has not been independently verified at time of writing and causal attribution is uncertain. Adulteration with the distinct species Uncaria guianensis in commercial markets is a documented risk and may contribute to variable safety and efficacy profiles [7].
Contraindications
Use during pregnancy is contraindicated based on traditional precaution and absence of controlled safety data; the plant has been used historically as an abortifacient in some South American traditional contexts, and no controlled clinical data exist to establish fetal safety [4, 7]. Concurrent use with immunosuppressant therapy requires medical supervision given documented immunomodulatory activity. Patients awaiting organ transplant or on anti-rejection medications should avoid use. Do not conflate with Uncaria rhynchophylla (Gou Teng, used in TCM for neurological applications) — the two species have different phytochemical profiles and distinct therapeutic and safety considerations [4, 7].
Clinical and phytochemical data
Used part
Root bark and inner bark (cortex). Bark from the woody vine stem is used in some preparations but root bark is the primary part used in pharmacological research and traditional medicine. Note: U. guianensis is a distinct species commonly adulterated into commercial cat's claw products — species verification is essential.
Primary active compounds
Pentacyclic oxindole alkaloids (POAs): isopteropodine, pteropodine, isomitraphylline, uncarine F, mitraphylline — primary immunomodulatory constituents
Tetracyclic oxindole alkaloids (TOAs): rhynchophylline, isorhynchophylline, corynoxeine — act on central nervous system; antagonise POA immunomodulatory effects
Quinovic acid glycosides (triterpenoid saponins) — anti-inflammatory, antiviral activity documented in vitro
Procyanidins and catechins — antioxidant activity
Sterols (beta-sitosterol, stigmasterol, campesterol)
Tannins (including epicatechin)
Mechanism of action
Based on in vitro and animal model evidence, the primary anti-inflammatory mechanism of Uncaria tomentosa involves inhibition of NF-κB nuclear translocation, suppressing transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 [2, 3]. Allen-Hall et al. demonstrated in THP-1 monocyte-like cells that U. tomentosa extract inhibits TNF-α production specifically through an NF-κB-dependent mechanism [2]. Immunomodulatory activity is attributed to the pentacyclic oxindole alkaloid (POA) fraction: POAs are proposed to stimulate the cellular immune system, potentially via effects on lymphocyte proliferation and phagocytic activity of macrophages. Critically, tetracyclic oxindole alkaloids (TOAs) act on the central nervous system through distinct receptor targets and are reported to pharmacologically antagonise the immunomodulatory effects of POAs in preclinical models — preparations that contain both chemotypes are considered therapeutically inferior for immune applications [4]. Antimutagenic activity in vitro has been demonstrated in bacterial assay systems (Salmonella typhimurium), though the precise mechanism has not been fully characterised and no human pharmacological mechanism studies have been conducted [5].
Pharmacokinetics
Absorption
Formal in vivo human pharmacokinetic studies for the POA fraction of Uncaria tomentosa have not been identified in the published literature. Based on the physicochemical properties of oxindole alkaloids as a class, variable and potentially incomplete oral absorption is anticipated, but bioavailability data in humans are not available.
Distribution
No formal human distribution data identified. Based on the lipophilic character of oxindole alkaloids and preclinical animal pharmacology, CNS penetration of TOA alkaloids is plausible and consistent with their documented CNS effects. Distribution volume for POA alkaloids in humans has not been characterised.
Metabolism
No formal human hepatic metabolism studies identified for the U. tomentosa POA alkaloid fraction. CYP3A4 involvement is plausible given structural similarity to other Rubiaceae indole alkaloids, but this has not been confirmed in human studies and drug interaction risk cannot be quantified from available evidence.
Excretion
No dedicated renal or biliary excretion data identified for U. tomentosa alkaloids in humans. Based on the lipophilic nature of oxindole alkaloids, partial faecal elimination is anticipated, but elimination half-life in humans is not established.
Safety and interactions
Drug interactions
Immunosuppressant drugs (cyclosporine, tacrolimus, corticosteroids, biologic DMARDs): documented immunostimulatory activity of POA alkaloids may theoretically antagonise immunosuppression — concurrent use requires medical supervision and is not recommended without specialist oversight. Anticoagulants and antiplatelet agents: preclinical data suggest antiplatelet-like activity of quinovic acid glycosides and catechins; additive bleeding risk is a theoretical concern requiring monitoring. CYP enzyme and transporter interactions: based on the structural class of oxindole alkaloids, interactions with CYP3A4 and drug efflux transporters are theoretically possible; clinical significance in humans has not been established in controlled studies. All interaction claims are based on pharmacological mechanism and general alkaloid class data; controlled clinical interaction studies are absent.
Toxicity
Toxicological review (Valerio and Gonzales, PMID 16042502) concludes that cat's claw demonstrates low acute toxicity in animal studies. No genotoxicity was detected in bacterial mutagenicity assays (Rizzi et al., PMID 8479203). A single case of allergic interstitial nephritis has been attributed to cat's claw in the herb nephrotoxicity literature; the original case report citation has not been independently confirmed at time of writing and causality is not established. Long-term human safety data from controlled trials are absent.
Special precautions
Pregnancy
Contraindicated during pregnancy. Uncaria tomentosa has been used historically as an abortifacient in some South American traditional contexts [4, 7]. No controlled human safety data exist. Avoid all use during pregnancy.
Lactation
Insufficient safety data for use during breastfeeding. Oxindole alkaloids may be excreted in breast milk given their lipophilic character. Avoidance is recommended in the absence of safety data.
Hepatic impairment
No formal pharmacokinetic or clinical safety studies in hepatic impairment have been identified. Alkaloid metabolism is expected to be hepatic. Caution is warranted in significant liver disease; use should be under medical supervision with liver function monitoring.
Renal impairment
A single case report of allergic interstitial nephritis attributed to cat's claw has been noted in the literature; causal attribution is uncertain and the original case report citation has not been independently confirmed at time of writing. No formal pharmacokinetic data in renal impairment are available. Caution is warranted in pre-existing renal disease; clinical monitoring recommended.
Sources and references
- [1] - Mur E et al. Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of uncaria tomentosa for the treatment of rheumatoid arthritis. J Rheumatol, 2002. PMID: 11950006
- [2] - Allen-Hall L et al. Uncaria tomentosa acts as a potent TNF-alpha inhibitor through NF-kappaB. J Ethnopharmacol, 2010. PMID: 19995599
- [3] - Sandoval-Chacón M et al. Antiinflammatory actions of cat's claw: the role of NF-kappaB. Aliment Pharmacol Ther, 1998. PMID: 9882039
- [4] - Reinhard KH. Uncaria tomentosa (Willd.) DC.: cat's claw, uña de gato, or saventaro. J Altern Complement Med, 1999. PMID: 10328636
- [5] - Rizzi R et al. Mutagenic and antimutagenic activities of Uncaria tomentosa and its extracts. J Ethnopharmacol, 1993. PMID: 8479203
- [6] - Valerio LG Jr, Gonzales GF. Toxicological aspects of the South American herbs cat's claw and Maca. Toxicol Rev, 2005. PMID: 16042502
- [7] - Marques O et al. Uncaria tomentosa as a Promising Natural Source. Int J Mol Sci, 2025. PMID: 40725012